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Abstract: Cervical cancer affects millions of Americans, but the rate for cervical cancer in the Mexican
American is approximately twice that for non-Mexican Americans. The etiologies of cervical cancer
are still not fully understood. A number of somatic mutations, including several copy number
alterations (CNAs), have been identified in the pathogenesis of cervical carcinomas in non-Mexican
Americans. Thus, the purpose of this study was to investigate CNAs in association with cervical
cancer in the Mexican American population. We conducted a pilot study of genome-wide CNA
analysis using 2.5 million markers in four diagnostic groups: reference (n = 125), low grade dysplasia
(cervical intraepithelial neoplasia (CIN)-I, n = 4), high grade dysplasia (CIN-II and -III, n = 5) and
invasive carcinoma (squamous cell carcinoma (SCC), n = 5) followed by data analyses using Partek.
We observed a statistically-significant difference of CNA burden between case and reference groups
of different sizes (>100 kb, 10–100 kb and 1–10 kb) of CNAs that included deletions and amplifications,
e.g., a statistically-significant difference of >100 kb deletions was observed between the reference
(6.6%) and pre-cancer and cancer (91.3%) groups. Recurrent aberrations of 98 CNA regions were also
identified in cases only. However, none of the CNAs have an impact on cancer progression. A total of
32 CNA regions identified contained tumor suppressor genes and oncogenes. Moreover, the pathway
analysis revealed endometrial cancer and estrogen signaling pathways associated with this cancer
(p < 0.05) using Kyoto Encyclopedia of Genes and Genomes (KEGG). This is the first report of CNAs
identified for cervical cancer in the U.S. Latino population using high density markers. We are aware
of the small sample size in the study. Thus, additional studies with a larger sample are needed to
confirm the current findings.
Keywords: cervical cancer; copy number alterations; genome wide analysis;
Mexican American population; Illumina HumanOmni2.5-8 BeadChip

somatic;

1. Introduction
Based on the U.S. Centers for Disease Control and Prevention (CDC) 2009 report, 12,357 women
were diagnosed with cervical cancer, and 3909 women died from cervical cancer in the United States.
This huge number of patients with cervical cancer has been a critical issue and is responsible for
10%–15% of cancer-related deaths in females globally [1]. Cervical cancer is the second most common
malignant tumor in women worldwide. Among these tumors, approximately 80% are squamous cell
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carcinomas (SCCs), and 5%–20% are adenocarcinomas (AdCAs) [2,3]. Cervical SCCs are developed
from a premalignant disease known as cervical intraepithelial neoplasia (CIN) Graded 1–3 with
increasing atypical features. The five-year overall survival for cervical cancer is only 66%.
In addition, increasing evidence suggests that infection with high-risk subtypes of human
papillomavirus (HPV) (e.g., HPV-16 and HPV-18) is the most common cause and is the primary initiator
of premalignant lesions [4]. However, only a small proportion of women infected with oncogenic
HPV subtypes develop cervical cancer, which suggests that HPV infection alone is insufficient to
cause cancer, and there is a possibility of other host factors linked to the development of invasive
cervical cancer [5], like genetic variation, including polymorphisms, insertions or deletions in the
host genome [6,7]. Increasing evidence demonstrates that there was a consistent relationship between
certain genetic variants (such as the tumor protein 53 (TP53) Arg72Pro polymorphism) and cervical
cancer, most likely modulated by the presence of high-risk HPV during progression from squamous
intraepithelial lesions (SIL) to cervical cancer.
Moreover, Mexican American women in Texas have among the highest rates of cervical cancer
incidence and mortality in the country [8] with twice the frequency as compared to their non-Mexican
American counterparts. The annual death rate from cervical cancer for Mexican Americans is 24.2 out
of 100,000 [9]. However, there is a lack of studies on somatic mutation identification for cervical cancer
in this population. Only four studies have reported on genetic basis of cervical cancer in Mexican
American women based on a PubMed search (19 November 2015). The number of the Mexican
American population was estimated at 50.5 million in the 2010 census, making Mexican American the
largest minority group in the U.S., as well as a rapidly growing segment of the U.S. population.
Recent advances in genome studies have led to the discovery of one important type of variation
that can be assessed with recent technology: copy number alterations (CNAs), usually for a cancer
study, somatic copy number changes and/or copy number variations (CNVs), usually for a non-cancer
study, or germline copy number changes, such as CNVs identified for neuropsychiatric disorders in
our recent study [10]. These CNAs or CNVs are by definition chromosomal regions with sizes of 1 kb
to several Mb, which vary across individuals with regard to the number of copies of a chromosomal
segment. CNVs refer to structural variations of the DNA that include insertions, deletions and
duplications. Studies have found that CNVs cover as much as 14% of the human genome [11], and
there is a much higher de novo rate as many as 10–1000-fold in CNVs as compared to single nucleotide
polymorphisms (SNPs) [11,12]. Furthermore, CNVs have been shown to account for more genomic
differences between individuals than SNPs [13,14]. Therefore, CNVs may contribute a sizeable amount
of disease phenotypic variation in each individual of a population [15].
Analyses integrating mutation information with data on rearrangements and CNAs have
revealed a higher-order organization of the seemingly random genetic events that lead to cancer [16].
Interestingly, genes in regions subject to copy number changes appear to be organized along functional
ontological terms related to cancer [16]. Studies have also implicated a number of somatic mutations,
including TP53, phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA),
phosphatase and tensin homolog (PTEN), serine/threonine kinase 11 (STK11) and V-Ki-ras2 Kirsten
rat sarcoma viral oncogene homolog (KRAS) [17,18], and several CNAs in the pathogenesis of cervical
carcinomas [19,20] in non-Mexican Americans.
In this study, we carried out a genome-wide survey of potential somatic CNAs, including
amplifications and deletions, in apparently normal tissues (n = 2), low grade dysplasia (n = 4), high
grade dysplasia (n = 5), invasive carcinoma (n = 5) and blood samples (n = 125, serving as a reference
group) of female subjects from the HapMap data. We are aware of the limited number of cases
and the lack of a control group. Thus, in the future, a large study with a control sample and more
cases as a methodological alternative is needed. We genotyped 2.5 million markers and analyzed
somatic CNAs in a total of 14 tissues using the Illumina HumanOmni2.5-8 BeadChip Kit at tissue-level
resolution. We mapped genomic changes: (1) between peripheral blood samples of the reference
subjects and cervical tissues from the cases (cervical dysplasia and invasive carcinoma); because only
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two normal cervical tissue samples had insufficient statistical power, we excluded these two samples
from the further analysis; (2) we also analyzed genomic changes among four diagnostic groups (normal,
low, high grade and invasive carcinoma). We expect that this study: (i) will provide an estimate of
the prevalence of somatic CNAs by identifying specific patterns, genes and/or biological pathways
associated with different stages of cervical dysplasia in Mexican Americans; (ii) will investigate
the genomic context of these somatic CNAs; and (iii) will evaluate whether the burden of somatic
mutations predicts tumor progression.
2. Materials and Methods
2.1. Materials
A total of 14 tissues (low, high grade dysplasia and invasive carcinoma) from cases and 125 female
subjects, serving as a reference group, were used for this study. The demographic information is shown
in Table 1. The cases were categorized into three groups, including low grade dysplasia (CIN-I, n = 4),
high grade dysplasia (CIN-II and III, n = 5) and squamous cell carcinoma (SCC, n = 5) groups. For a
broader definition of the case group, we also divided the cases into two groups, pre-cancer (CIN-I,
-II and -III) and cancer (SCC). All of the case subjects in the current study were from the Mexican
American population recruited from the outpatient clinics at the University Medical Center (UMC)
and Texas Tech University Health Sciences Center (TTUHSC)-El Paso. All cases of cervical cancer
were diagnosed as SCC by histopathological examinations, whereas healthy women had no abnormal
cytological findings in the Pap smear tests of the uterine cervix.
Table 1. Clinical demographics with diagnosis, age for cases and reference subjects.
Subject ID

Age (years)

Diagnosis 1

Diagnosis 2

Diagnosis 3

14
16
17
15
12
8
11
6
5
3
4
2
7
1
n = 125 females

42
24
53
31
27
39
21
30
38
55
44
51
31
42
NA

CIN-I
CIN-I
CIN-I
CIN-I
CIN-II
CIN-III
CIN-III
CIN-III
CIN-III
SCC
SCC
SCC
SCC
SCC
reference

low grade dysplasia
low grade dysplasia
low grade dysplasia
low grade dysplasia
high grade dysplasia
high grade dysplasia
high grade dysplasia
high grade dysplasia
high grade dysplasia
SCC
SCC
SCC
SCC
SCC
reference

pre-cancer
pre-cancer
pre-cancer
pre-cancer
pre-cancer
pre-cancer
pre-cancer
pre-cancer
pre-cancer
SCC
SCC
SCC
SCC
SCC
reference

All subjects in the cases were human papillomavirus (HPV) positive and from the Mexican American population.
Reference subjects were from an admixed population. NA, not available. CIN, cervical intraepithelial neoplasia;
SCC, squamous cell carcinoma.

The Illumina HumanOmni2.5-8 BeadChip data from a total of 125 blood samples of female
subjects from the HapMap were used as a reference in the current study.
2.2. Methods
2.2.1. Tissue Specimens
Sixteen cervical tissue samples were obtained from the Department of Pathology, TTUHSC-El
Paso. We excluded two normal tissues due to an insufficient tissue sample size. All case subjects
were HPV positive, from the Mexican American population and had signed Institutional Review
Board-approved written informed consent forms prior to enrolling in the study. The procedures were
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approved by the Institutional Review Boards of TTUHSC (IRB #E13107), and the study was performed
in accordance with the Helsinki Declaration of 1975.
2.2.2. Microdissection
Paraffin-embedded tissues were first sectioned into 10-µm slices, which were hematoxylin-eosin
stained for the selection of the appropriate tissue area. The corresponding selected areas of each tissue
sample were then collected under microscopic observation with a 30-gauge needle (Becton-Dickinson,
Franklin Lakes, NJ, USA).
Genomic DNA of micro-dissected tissue was extracted by proteinase K digestion followed by
standard phenol-chloroform extraction. The QIAamp Formalin-Fixed, Paraffin-Embedded (FFPE)
Tissue Kit from Qiagen (Valencia, CA, USA), which is widely used for extracting DNA from FFPE
sections, was used. The experiment was performed according to the manufacturer’s handbook. The
total amount of DNA was spectrophotometrically determined by measuring the absorbance at 260 nm
(A260), and DNA purity was assessed by detecting the A260/A280 ratio using the Varioskan Flash
(Thermo Scientific, Rockford, IL, USA) according to the manufacturer’s instructions.
2.2.3. High Density Genotyping
Genomic DNA from the case group was used to obtain genotypes by the Illumina
HumanOmni2.5-8 BeadChip (Illumina, San Diego, CA, USA). This DNA chip provided over 2.5 million
markers at a median spacing of 1.2 kb and full support of CNV or CNA applications, which was a
powerful genotyping tool and allowed us to make more meaningful discoveries. Genomic annotations
were based on National Center for Biotechnology Information (NCBI) Human Genome Build 37
(University of California, Santa Cruz Genome Browser Release 19), and genotyping experiments were
performed at the Genomics Core at the TTUHSC-El Paso.
Due to our limited number of control samples of cervical tissues, we used publicly available
HapMap data with genotypes, including CNV data of the same DNA chip, the Illumina
HumanOmni2.5-8 BeadChip Kit, in the 125 female subjects as a reference group. The HapMap
data with genotypes were downloaded from [21].
In addition, there is no genotype data available for the Mexican American population using the
HapMap data, so we selected these 125 female subjects from the Admix populations (Utah residents
with Northern and Western European ancestry, CEU; Yoruba, YRI; Han Chinese, CHB, and Japanese,
JPT) since the various combinations of reference panels with the multi-ethnic populations had
better accuracy than those containing only single ethnic samples [22] for genetic study and genetic
imputation analysis.
The raw genotyping signal data were processed by the Illumina GenomeStudio software
Genotyping Module Version 3.2.33 (Illumina) and converted to allele-specific intensity values.
The genotype call rate threshold was set at ě95% for all samples, and a total of 139 including case
(n = 14) and reference (n = 125) subjects passed the quality control. A Partek customized report of the
normalized genotype data, composed of those 139 samples, including low grade (CIN-I = 4), high
grade (CIN-II and CIN-III = 5), SCC (n = 5) and 125 females from the reference group (Table 1), was
transferred to Partek® Genomic Suite® software, Version 6.6, Copyright 2014, Partek Inc. (Saint Louis,
MO, USA), for downstream analysis.
2.2.4. CNA Detection
Unpaired copy number analysis was performed in the Partek Genomics Suite comparing allele
intensities to a reference baseline of 125 female HapMap admixed samples using a similar analysis
strategy as a previous publication [23]. The genomic segmentation algorithm was applied to find break
points and to detect amplifications (gains) and deletions (losses). The following stringent parameters
were used to identify CNAs and CNA regions as a previous study [24]: (1) each segment must contain
a minimum of 10 consecutive filtered probe sets; (2) a p value threshold of 0.001 when compared to
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We further examined whether these CNAs in the various genes have an impact on gene
functions. Gene ontology (GO) analysis was also performed using the Partek® Genomic Suite®
thesoftware,
neighboring
adjacent
regions;®and
(3)Partek
a signal-to-noise
threshold
of 0.5there
and was
diploid
copy number
Version
6.6, Copyright
2014,
Inc., to investigate
whether
enrichment
for
CNAs (p < 0.05) in genes from any ontology categories.
1.7cancer‐associated
to 2.3.
Disease association of individual CNA frequencies with patients, as a group, compared to a
2.2.5.
Pathway
Analysis
reference group,
was assessed using 2 × 2 or 2 × 3 contingency tables, two‐tailed χ2 tests or Fisher
exact tests. Statistical analyses were performed using the SPSS statistical software package
We further examined whether these CNAs in the various genes have an impact on gene
(Version 10, IBM, Chicago, IL, USA). Differences with two‐tailed probability values®of p ≤ 0.05 were ®
functions. Gene ontology (GO) analysis was also performed using the Partek Genomic Suite
taken as statistically significant. p‐values for tests of CNA association were conservatively corrected
software, Version 6.6, Copyright® 2014, Partek Inc., to investigate whether there was enrichment for
for multiple testing using the Bonferroni method.
cancer-associated CNAs (p < 0.05) in genes from any ontology categories.
Disease association of individual CNA frequencies with patients, as a group, compared to a
3. Results
reference group, was assessed using 2 ˆ 2 or 2 ˆ 3 contingency tables, two-tailed χ2 tests or Fisher exact
tests.
analyses
3.1. Statistical
Overall CNA
Patternswere performed using the SPSS statistical software package (Version 10, IBM,
Chicago, IL, USA). Differences with two-tailed probability values of p ď 0.05 were taken as statistically
We processed genotype and intensity data for all 2.5 million probes of the Illumina
significant. p-values for tests of CNA association were conservatively corrected for multiple testing
HumanOmni2.5‐8 BeadChip Kit for the 14 cases and 125 reference subjects. A number of CNAs
using
the Bonferroni
(deletions
or losses)method.
was present in many chromosomal regions (Figure 1). A total of 2220 CNAs
>1000 bp was identified, including 725 (32.7%) amplifications (gains) and 1495 (67.3%) deletions
3. Results
(losses) mainly on the 22 autosomal chromosomes.
The chromosomal
3.1. Overall
CNA Patternslocations of the copy number amplifications and deletions of the 22 autosomes
and X chromosomes were shown by karyograms (Figure 1). Most of the amplifications are found in
processed
genotype
intensity 1,data
alland
2.520,
million
of the Illumina
theWe
cases
at the short
arms of and
chromosomes
5, 8, for
16, 19
as wellprobes
as the centromeres
of
HumanOmni2.5-8
BeadChip
Kit
for
the
14
cases
and
125
reference
subjects.
A
number
CNAs
chromosomes 14, 15 and 21. Most of the deletions in the cases were mainly observed at the shortofarms
(deletions
or losses)
in 17
many
regions
(Figure
A total of19.
2220 CNAs
of chromosomes
1, 4,was
5, 7,present
11, 12, 16,
and chromosomal
19, as well as the
centromeres
of 1).
chromosome
>1000 bp was identified, including 725 (32.7%) amplifications (gains) and 1495 (67.3%) deletions (losses)
mainly on the 22 autosomal chromosomes.

Figure 1. Karyogram view of detected amplified and deleted regions across autosomes.
Figure 1. Karyogram view of detected amplified and deleted regions across autosomes. Amplifications
Amplifications
are shown at right side of the chromosomes, and deletions are shown at the left side
are shown at right side of the chromosomes, and deletions are shown at the left side of the chromosomes.
of the
chromosomes. The length of the horizontal bar corresponds to the number of samples observed
The length of the horizontal bar corresponds to the number of samples observed at the respective
at the
respective cytobands. Most of the amplifications were found in cases at the short arms of
cytobands. Most of the amplifications were found in cases at the short arms of chromosomes 1, 5,
chromosomes 1, 5, 8, 16, 19 and 20, as well as the centromeres of chromosomes 14, 15 and 21. Most of
16, 19 and 20, as well as the centromeres of chromosomes 14, 15 and 21. Most of the deletions in
the8,deletions
in the cases were mainly observed at the short arms of chromosomes 1, 4, 5, 7, 11, 12,
the cases were mainly observed at the short arms of chromosomes 1, 4, 5, 7, 11, 12, 16, 17 and 19, as
16, 17 and 19, as well as the centromere of chromosome 19. We observed a statistically‐significant
well as the centromere of chromosome 19. We observed a statistically-significant difference of CNA
difference
of CNA burden between case and reference groups (Table 2) for different sizes of CNAs
burden between case and reference groups (Table 2) for different sizes of CNAs (>100 kb, 10–100 kb
and 1–10 kb). For example, statistically-significant differences of >100 kb, 10–100 kb and 1–10 kb
deletions were observed between reference (6.7%, 2.5%, 0.8%), pre-cancer (92.5%, 81.5%, 87.7%) and
cancer (89.0%, 76.7%, 86.6%) groups, respectively (Table 2).
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Table 2. Copy number alteration (CNA) burden (deletion and amplification) among different diagnostic groups.
2A
Size of CNAs

Reference (n = 122)
All

>100 kb
10–100 kb
1 kb–10 kb

212
157
128

Amplification Deletion
(%)
(%)
198 (93.3)
14 (6.7)
153 (97.5)
4 (2.5)
127 (99.2)
1 (0.8)

Low (n = 4)
All
156
119
125

Amplification Deletion
(%)
(%)
15 (9.6)
141 (90.4)
24 (20.2)
95 (79.8)
11 (8.8)
114 (91.2)

High (n = 5)
All
244
183
193

SCC (n = 5)

Amplification Deletion
(%)
(%)
15 (6.1)
229 (93.9)
32 (17.5)
151 (82.5)
28 (14.5)
165 (85.5)

All
218
163
179

Amplification Deletion
(%)
(%)
24 (11)
194 (89)
38 (23.3)
125 (76.7)
24 (13.4)
155 (86.6)

2B
Size of CNAs

Reference
All

>100 kb
10–100 kb
1 kb–10 kb

212
157
128

Amplification Deletion
(%)
(%)
198 (93.3)
14 (6.7)
153 (97.5)
4 (2.5)
127 (99.2)
1 (0.8)

Pre-Cancer (n = 9)
All
400
302
318

Amplification Deletion
(%)
(%)
30 (7.5)
370 (92.5)
56 (18.5)
246 (81.5)
39 (12.3)
279 (87.7)

Cancer (n = 5)
All

Amplification (%)

Deletion (%)

218
163
179

24 (11)
38 (23.3)
24 (13.4)

194 (89.0)
125 (76.7)
155 (86.6)
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The chromosomal locations of the copy number amplifications and deletions of the 22 autosomes
and X chromosomes were shown by karyograms (Figure 1). Most of the amplifications are found
in the cases at the short arms of chromosomes 1, 5, 8, 16, 19 and 20, as well as the centromeres of
chromosomes 14, 15 and 21. Most of the deletions in the cases were mainly observed at the short arms
Med. Sci. 2016,
8 of 18
of chromosomes
1, 4,4,125, 7, 11, 12, 16, 17 and 19, as well as the centromeres of chromosome
19.
3.2. Principal Component Analysis (PCA)

3.2. Principal Component Analysis (PCA)

To characterize aberration profiles in different diagnostic groups (low grade dysplasia, high

To characterize
aberration
inwe
different
diagnostic
groups
(lowwas
grade
dysplasia,
high grade
grade dysplasia,
SCC and profiles
reference),
performed
a PCA (Figure
2). There
a great
variability
in
the
three
diagnostic
groups
(reference,
pre‐cancer
and
cancer)
and
four
diagnostic
groups
dysplasia, SCC and reference), we performed a PCA (Figure 2). There was a great variability in the
(reference,
low grade,
high grade
and SCC). and
Thesecancer)
results indicate
thatdiagnostic
there is a distinct
difference
three diagnostic
groups
(reference,
pre-cancer
and four
groups
(reference, low
in the patterns of the CNAs between case and reference groups based on the genomic profiles of these
grade, high
grade
and
SCC).
These
results
indicate
that
there
is
a
distinct
difference
in
the patterns of
subjects.
the CNAs between
groups
basedtheonreference
the genomic
ofwhen
these
subjects.
Overall,case
thereand
was reference
a clear separation
between
and the profiles
case group
examined
by PCA clustering.
A

B

Figure 2. Plot of principal component analysis (PCA) and hierarchical clustering of copy number

Figure 2. Plot of principal component analysis (PCA) and hierarchical clustering of copy number
variation (CNV) or CNA datasets. (A) PCA scatter plot of three diagnostic groups (pre‐cancer, cancer
variation and
(CNV)
or CNA
(A) PCA
scatter
plotPoints
of three
diagnostic
groups
cancer
reference).
Eachdatasets.
point represents
a specific
sample.
are colored
by group
status,(pre-cancer,
with blue
representing
(CIN‐I, ‐II and
‐III), redsample.
representing
invasive
cancer andby
green
representing
and reference).
Eachpre‐cancer
point represents
a specific
Points
are colored
group
status, with blue
references.
(B) PCA
scatter -II
plotand
of four
diagnostic
groups. Eachinvasive
point represents
specific
sample.
representing
pre-cancer
(CIN-I,
-III),
red representing
canceraand
green
representing
references. (B) PCA scatter plot of four diagnostic groups. Each point represents a specific sample.
Points are colored by group status, with blue representing low grade (CIN-I), red representing high
grade (CIN- II and -III), purple representing invasive cancer and green representing references.
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Overall, there was a clear separation between the reference and the case group when examined
by PCA clustering.
3.3. Genome-Wide CNA and Cancer Progression
Increasing evidence demonstrates that more numerical genomic alterations are associated with
progression from precursor lesions to invasive cancer [25]. Thus, we conducted CNA genomic analysis
in different diagnostic groups to understand the complexities of the genomic architecture of these highly
heterogeneous groups of cervical cancer and to assess whether CNA burden impacts the prognosis
of cervical cancer in this Mexican American population. We analyzed CNAs among two (pre-cancer
and cancer; Table 2B) and three diagnostic groups (low grade, high grade and SCC; Table 2A) in
cases only. There was no statistically-significant difference of CNA burden among diagnostic groups
in cases in any size of CNA, although there are slightly higher frequencies of amplifications in the
100 kb, 10–100 kb and 1–10 kb categories in the cancer group (11.0%, 23.3% and 13.4%, respectively) as
compared to the pre-cancer group (7.5%, 18.5% and 12.3%, respectively) (Table 2) using 205 two-tailed
χ2 tests with the SPSS statistical software package.
3.4. Recurrent Aberrations Identified in Cases Only
We are interested in recurrent CNAs since the chromosome regions with recurrent CNAs more
likely to harbor disease-critical genes are those that show alterations that are recurrent among
individuals with cancer or other diseases [26,27]. In this context, we can define a recurrent CNA
region as a set of contiguous genes (a region) that shows a high enough probability (or evidence) of
being altered (e.g., deletion or insertion) in two or more samples, as previously described [28]. The
recurrent aberrations in a total of 98 CNA regions containing 849 genes/loci were identified only in
the case group (pre-cancer and cancer subjects) with at least two cases who carried these CNAs. None
of these CNAs were observed in the reference group (Table 3). Among these 98 recurrent CNA regions,
there were 545 deletions (84%) and 104 amplifications (16%) observed in cases only using statistical
analyses described in the Methods section.
Table 3 shows the top 20 chromosome regions with a high number of recurrent somatic CNAs
(>100 kb) in the cases with at least nine subjects carrying these deletions in each CNA region; none of
these CNAs were observed in the reference group. Some of the CNAs contain tumor suppressor genes
(e.g., axis inhibition protein 1 (AXIN1) and tuberous sclerosis complex 2 (TSC2)).
Eight exceptionally large CNA regions with deletions of between 1591 kb and 517 kb were
detected in cases on short arms of chromosomes 1, 16 and 19.
In addition to recurrent deletions identified in the cases (Table 3), two recurrent CNA regions
with a 220-kb amplification on 21q11.2 and a 113.5-kb deletion on 7p22.2 were observed in only CIN-III
and SCC.
Next, we checked the Cervical Cancer Database (CCDB) [29] and found three genes, haemoglobin
alpha 2 (HBA2), mesothelin (MSLN) and STK11, overlapped between 849 genes/loci observed from
our current study and 538 genes listed in the CCDB.
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Table 3. Top 20 CNA chromosome regions with recurrent somatic CNAs (deletions >100 kb) in the cases; not observed in the reference group.
Cytoband

Start

Stop

# of Sub. with Del*.

Deletions in Subjects

No. of Markers

Length (bp)

Cancer-Related Genes

19p13.3
19p13.3
16p13.3
19p13.3
1p36.33-1p36.32
1p36.32
16p13.3
1p36.33
16p13.3
7p22.3
19p13.3
16p13.3
16p13.3
16p13.3
1p36.33
16p13.3
1p36.33
19p13.3
19p13.3
19p13.3

766,463
2,860,429
895,986
3,984,025
1,825,510
2,545,368
377,287
1,282,654
2,816,699
93,965
366,342
2,408,963
84,130
2,132,651
1,021,380
1,888,316
810,836
2,532,493
2,367,858
254,506

2,357,625
3,984,025
1,883,511
4,738,536
2,545,368
3,230,848
895,986
1,799,975
3,271,935
534,503
762,497
2,706,379
377,287
2,397,391
1,282,654
2,115,231
1,021,380
2,735,499
2,532,493
365,334

10
10
10
9
9
9
10
9
8
8
10
8
10
10
9
10
9
10
10
10

I (2), II (1), III (3), SCC (4)
I (2), II (1), III (3), SCC (4)
I (2), II (1), III (3), SCC (4)
I (2), II (1), III (3), SCC (3)
I (2), II (0), III (3), SCC (4)
I (2), II (0), III (3), SCC (4)
I (2), II (1), III (3), SCC (4)
I (2), II (0), III (3), SCC (4)
I (2), II (0), III (3), SCC (3)
I (2), II (0), III (3), SCC (3)
I (2), II (1), III (3), SCC (4)
I (2), II (0), III (3), SCC (3)
I (2), II (1), III (3), SCC (4)
I (2), II (1), III (3), SCC (4)
I (2), II (0), III (3), SCC (4)
I (2), II (1), III (3), SCC (4)
I (2), II (0), III (3), SCC (4)
I (2), II (1), III (3), SCC (4)
I (2), II (1), III (3), SCC (4)
I (2), II (1), III (3), SCC (4)

1497
1154
1022
672
732
678
525
242
469
265
604
142
284
141
233
210
221
228
191
108

1,591,163
1,123,597
987,526
754,512
719,859
685,481
518,700
517,322
455,237
440,539
396,156
297,417
293,158
264,741
261,275
226,916
210,545
203,007
164,636
110,829

STK11
MATK, DAPK3
AXIN1
HES5
PRDM16
AXIN1, MSLN
BSG, FGF22, AXIN1
HBA2
AXIN1
TSC2

# of Sub. with Del *: number of subjects with deletion. Serine/threonine kinase 11 (STK11); maturase K (MATK); Death-associated protein kinase 3 (DAPK3); axis inhibition protein 1
(AXIN1); hairy/enhancer of split, drosophila, homolog of, 5 (HES5); PR domain containing 16 (PRDM16); mesothelin (MSLN); basignin (BSG); fibroblast growth factor 22 (FGF22);
haemoglobin A2 (HBA2); tuberous sclerosis complex 2 (TSC2).
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3.5. CNA Regions Contained Known Tumor Suppressor Genes and Oncogenes in Cancer Tissues but Not in the
Reference Group
We were also interested in identifying CNA regions that were observed only in cases and over
100 kb containing known cancer-related genes as compared to the references (Tables 3–5). Thus, we
examined whether newly-identified CNAs contained tumor suppressor genes and/or oncogenes.
We observed a total of 26 CNA regions containing known tumor suppressor gene regions. These
CNAs were deletions and only seen in the case group. Furthermore, none of these regions were
observed in the reference group (Table 4). We also observed a total of six CNA regions with deletions
(no amplification) containing known oncogenes in the case group, and none of these regions were
observed in the reference group (Table 5).
Table 4. Newly-identified CNAs (deletions) contain known oncogenes in cases only.
Query Position
chr4:1694786–1937978
chr4:1937978–2141625
chr19:6194240–6239714
chr19:6239714–6598484
chr19:6679537–6796128
chr19:6796128–6883617

Gene Name

Gene ID

Length (bp)

Deletions in Different Diagnostic Groups

WHSC1
WHSC1
MLLT1
MLLT1
VAV1
VAV1

7468
7468
4298
4298
7409
7409

243,193
203,648
45,475
358,771
116,592
87,490

ref (0), I (1), II (0), III (3), SCC (1)
ref (0), I (1), II (0), III (3), SCC (1)
ref (0), I (2), II (0), III (2), SCC (1)
ref (0), I (2), II (0), III (2), SCC (1)
ref (0), I (2), II (0), III (1), SCC (1)
ref (0), I (2), II (0), III (1), SCC (1)

Wolf-Hirschhorn syndrome candidate 1 (WHSC1); myeloid/lymphoid leukemia; translocated to 1 (MLLT1);
vav guanine nucleotide exchange factor 1 (VAV1).

Table 5. Newly-identified CNAs (deletions) contain known tumor suppressor genes in cases only.
Query Position
chr1:3252272–3613519
chr1:3613519–3615102
chr1:3615102–3615341
chr1:3615341–3621322
chr1:3621322–4125280
chr5:204517–422812
chr5:422812–582058
chr7:1216332–1963055
chr7:1963055–1964889
chr7:1964889–2219927
chr7:2219927–2770642
chr16:1888316–2115231
chr16:2115231–2116240
chr16:2116240–2127184
chr16:2127184–2132651
chr16:2132651–2397391
chr16:377287–895986
chr16:84130–377287
chr17:1586256–1692127
chr17:1692127–1737406
chr19:5310257–5598484
chr19:5598484–5623377
chr19:5598484–5623377
chr19:5623377–5625242
chr19:5625242–5625729
chr19:5625729–5846816

Gene Name

Gene
ID

Length
(bp)

Deletions in Different
Diagnostic Groups

TP73
TP73
TP73
TP73
TP73
AHRR
AHRR
MAD1L1
MAD1L1
MAD1L1
MAD1L1
TSC2
TSC2
TSC2
TSC2
TSC2
AXIN1
AXIN1
SMYD4
SMYD4
SAFB2
SAFB2
SAFB
SAFB
SAFB
SAFB

7161
7161
7161
7161
7161
57491
57491
8379
8379
8379
8379
7249
7249
7249
7249
7249
8312
8312
114826
114826
9667
9667
6294
6294
6294
6294

361,248
1584
240
5982
503,959
218,296
159,247
746,724
1835
255,039
550,716
226,916
1010
10,945
5468
264,741
518,700
293,158
105,872
45,280
288,228
24,894
24,894
1,866
488
221,088

ref (0), I (1), II (0), III (3), SCC (3)
ref (0), I (1), II (0), III (3), SCC (3)
ref (0), I (1), II (0), III (3), SCC (3)
ref (0), I (1), II (0), III (3), SCC (3)
ref (0), I (1), II (0), III (2), SCC (2)
ref (0), I (1), II (0), III (3), SCC (2)
ref (0), I (1), II (0), III (3), SCC (2)
ref (0), I (2), II (0), III (3), SCC (3)
ref (0), I (2), II (0), III (3), SCC (3)
ref (0), I (2), II (0), III (3), SCC (3)
ref (0), I (2), II (0), III (3), SCC (3)
ref (0), I (2), II (1), III (3), SCC (4)
ref (0), I (2), II (1), III (3), SCC (4)
ref (0), I (2), II (1), III (3), SCC (4)
ref (0), I (2), II (1), III (3), SCC (4)
ref (0), I (2), II (1), III (3), SCC (4)
ref (0), I (2), II (1), III (3), SCC (4)
ref (0), I (2), II (1), III (3), SCC (4)
ref (0), I (1), II (0), III (3), SCC (1)
ref (0), I (1), II (0), III (3), SCC (1)
ref (0), I (2), II (0), III (3), SCC (3)
ref (0), I (2), II (0), III (3), SCC (3)
ref (0), I (2), II (0), III (3), SCC (3)
ref (0), I (2), II (0), III (3), SCC (3)
ref (0), I (2), II (0), III (3), SCC (3)
ref (0), I (2), II (0), III (3), SCC (3)

Reference (0), I (1), II (0), III (3), SCC (3) means a 361-kb deletion on chromosome 1 occurred in one subject with
CIN-I, 3 subjects with CIN-III and 3 subjects with SCC.
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3.6. Pathway Analysis
Recent studies have incorporated protein networks into the results of genome-wide CNA data
using networks or GO analysis to discover disease-associated and/or enriched pathways [30–33].
Therefore, we conducted GO analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway analysis.
The results of the functional enrichment of KEGG pathway analysis in the identified CNAs
>100 kb that occurred in two or more cases are shown in Table 6. Fourteen pathways were discovered,
including the insulin signaling pathway and the endometrial cancer and estrogen signaling pathway,
with enrichment p values lower than 0.05. A GO analysis was performed by selecting CNAs in the
genes to see if any GO categories were overrepresented among CNAs identified in cases [34]. Many
biological processes were undisturbed at the molecular level, while others were frequently affected
across multiple cases, as shown in Table 7, which lists the most commonly-affected function with
p-values lower than 0.05 and more than four genes in each function category.
Table 6. Functional enrichment of Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway
analysis in the identified CNAs (>100 kb and occurring in two or more patients with SCC).
Pathway Name
Insulin signaling pathway
Endometrial cancer
Parkinson’s disease
Glioma
Huntington’s disease
NF-κB signaling
Ribosome
Alcoholism
Neurotrophin signaling pathway
Estrogen signaling pathway
RNA polymerase
Dopaminergic synapse
PI3K-Akt signaling pathway
Ubiquitin-mediated proteolysis

Enrichment
Score

Enrichment p
Value

% Genes in
Pathway

# Gene in List

KEGG
Pathway ID

4.749
4.698
4.054
3.713
3.640
3.572
3.522
3.495
3.399
3.326
3.195
3.042
3.038
3.005

0.009
0.009
0.017
0.024
0.026
0.028
0.030
0.030
0.033
0.036
0.041
0.048
0.048
0.049

7.03
10.64
7.22
8.33
5.84
7.14
7.06
5.70
6.31
6.75
10.71
5.83
4.52
5.79

9
5
7
5
9
6
6
9
7
6
3
7
14
7

16
11
215
182
52
163
275
191
50
154
238
20
262
175

# ě6 genes in each function were listed here.

Table 7. Gene ontology (GO) categories of CNAs (>100 kb and occurring in two or more than two
patients with SCC).
Type

Function

Enrichment
Score

Enrichment
p Value

% Genes
in Group

# Genes
in List

GO ID

Molecular function

signal transducer activity
molecular transducer activity
enzyme binding
protein kinase binding
kinase binding

5.344
4.780
3.089
5.858
5.405

0.005
0.008
0.046
0.003
0.004

0.477
0.430
0.376
0.998
0.879

7
7
5
4
4

4871
60089
19899
19901
19900

Cellular component

membrane-bounded vesicle
vesicle
plasma membrane
plasma membrane part
plasma membrane protein complex
membrane protein complex

4.420
4.193
3.061
3.388
5.500
3.203

0.012
0.015
0.047
0.034
0.004
0.041

0.338
0.326
0.271
0.328
0.903
0.457

9
9
9
7
4
4

31988
31982
5886
44459
98797
98796

Biological process

signal transduction
cell surface receptor signaling pathway
regulation of signal transduction
positive regulation of gene expression
macromolecular complex subunit organization
G-protein coupled receptor signaling pathway
negative regulation of response to stimulus
defense response
positive regulation of protein metabolic process

4.648
4.546
3.443
3.992
3.303
4.089
3.821
3.783
3.569

0.010
0.011
0.032
0.018
0.037
0.017
0.022
0.023
0.028

0.291
0.344
0.332
0.413
0.354
0.489
0.457
0.452
0.428

12
9
7
6
6
5
5
5
5

7165
7166
9966
10628
43933
7186
48585
6952
51247

# ě6 genes in each function were listed here.
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4. Discussion
It has been demonstrated that somatic structural alterations (e.g., amplifications or deletions) of
human chromosomes represent a common class of mutations, which may cause gene disruption
(e.g., deletion or rearrangement), gene activation (e.g., CNAs, gain or amplification) or the
formation of novel oncogenic gene products (gene fusions). Many of these events actively drive
carcinogenesis [35,36]. In our initial cervical cancer cohort, some CNA patterns identified were
previously found to be correlated with cervical cancer.
We screened whole genomes with 2.5 million markers of an array to discover any recurrent copy
number alterations in cases (pre-cancer and SCC). We identified a total of 98 CNA regions >100 kb in
the case group, including low grade dysplasia, high grade dysplasia and SCC. These CNAs occurred
in two or more cases, including two large deletions (1591 kb and 1123 kb) (Table 3). Of the top 20
CNA regions >100 kb deletions in cases only, six CNAs occurred on 16p13 that have been reported
in cervical cancer [37], and mutation analysis of the AXIN1 gene located at 16p13 was reported to be
involved in the Wnt pathway in cervical carcinomas [38]. The CNA containing the SET and MYND
domain-containing protein 4 (SMYD4) gene on 17p13.3 was also reported previously in this cancer [37].
The SMYD4 gene is demonstrated to be a potential tumor suppressor and plays a critical role in breast
carcinogenesis, at least partly through inhibiting the expression of platelet-derived growth factor
receptor-alpha (PDGFRA), and this gene could be a novel target for improving the treatment of breast
cancer [39].
A number of previous studies demonstrate that numerical chromosomal aberrations were found
to progress to invasive cancer from precursor lesions [25,37]; however, we did not observe this
feature in our current study sample. This might be due to the small sample size or any other
unknown or not yet identified factors, such as ethnicity, since most previous study populations
are non-Hispanic populations.
Among two amplifications identified in CIN-III and SCC, one recurrent CNA region with a 220-kb
amplification on 21q11.2 was observed in CIN-III and co-occurred with previous findings, where the
amplification had been identified in breast cancer subjects with tamoxifen resistance [40].
The recurrent CNA regions we identified contain a number of tumor suppressor genes, oncogenes
and cancer-related genes. A CNA that contains the interferon-induced transmembrane protein 1
(IFITM1) gene at 11p15.5 was identified in eight cases. This gene has been reported to be involved
in cervical carcinogenesis [41]. A total of nine cases with the CNA containing the fucosyltransferase
3 (FUT3) gene at 19p13.3 were observed in the current study, and this gene is associated with
breast cancer [42]. A CNA region that includes the naked cuticle 2 (NKD2) gene at 5p15.35 was
detected in six cases. This gene was found to suppress breast cancer proliferation by inhibiting Wnt
signaling [43]. The ovarian cancer-associated gene 2 protein (OVCA2) at 17p13.3 was repeatedly
reported to be associated with ovarian cancer, and we observed five cases carrying the CNA at this
gene region. A cluster of three tumor suppressor genes, cadherin 1 (CDH1), death-associated protein
kinase (DAPK) and hypermethylated in cancer 1 (HIC1), displayed a significantly increased frequency
of promoter methylation with progressively more severe cervical neoplasia. In addition, the Hes family
BHLH Transcription Factor 5 (HES5) gene was reported to be associated with cervical carcinoma
cells using immunocytochemistry, Western blot and methyl thiazolyl tetrazolium assays [44], and
the CNAs on 1p36.33-1p36.32 containing the HES5 gene were also identified in the current study.
Our newly-identified CNA containing this gene on 7p22.2 was also observed in the recurrent pre-cancer
and cancer subjects (Table 3).
Moreover, we also examined deletion burden observed to be similar to those for other cancers and
found more deletions identified than amplification in most of the cancer studies, which supports our
findings. A recent study using the TCGA data identified nine regions of deletion that were unique to
estrogen receptor positive (ER+) post menopause tumors in patients with breast cancer [45], including
deletion in 7p22.3, where our newly-identified deletion in cases only was located, and it contains a
known tumor suppressor gene.
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To analyze the possible effect of genomic alterations, to further capture cancer-causing gene
information and to see whether any GO categories are overrepresented among CNA regions, we
searched the KEGG pathway database and GO categories and identified a number of pathways and
functions where CNAs occur in the SCC group, but not in the reference group (Tables 6 and 7).
Furthermore, our results were partly in agreement with previous reports about cervical cancer.
For example, using the functional enrichment of KEGG pathway analysis, we discovered the insulin
signaling pathway in the case group, and it was evidenced that HPV 16 E6 oncoprotein interferes with
the insulin signaling pathway by binding to tuberin [46]. As is already known, high-risk HPV infection
is a causal agent for cervical cancer. In addition, two pathways of interest are endometrial cancer and
the estrogen signaling pathway observed in the current study. The NF-κB signaling pathway was
also identified in our cancer group (SCC), but not in the reference group, which supports a previous
study where bisphenol A (BPA) stimulated the cervical cancer migration via IKK-β/NF-κB signals [47].
The estrogen signaling pathway was also shown in our KEGG analysis. A previous study was
performed to evaluate the potential of miRNAs as novel markers for the post-therapeutic monitoring
of cervical SCC patients. A regulatory network of differentially-expressed serum miRNAs was
identified, and a number of target genes was predicted in the estrogen-mediated signal pathways [48].
Ours and others’ findings support that cervical cancer is a hormone-associated gynecological disease.
For example, HPV infection has been associated with the deregulation of the PI3K-Akt-mTOR pathway
in invasive cervical carcinomas [49]. The PI3K-Akt signaling pathway was also found in our current
study, and 14 genes in this pathway were found in two or more SCC cases (Table 6).
Moreover, signal transducer activity with an enrichment score of 4.2 and a p value of 0.01
containing 11 genes was also identified in a previous report on cervical cancer [50] using GO analysis.
Signal transduction was identified in our current study in cervical cancer (SCC), but not in the reference
group; a recent study also supports that a signal transduction cascade and mitogen-activated protein
kinase kinase kinase 3 (MEKK3) serve as key integration points and are important factors in regulating
cellular responses to environmental stress. This signal transduction and MEKK3 not only link diverse
extracellular stimuli to subsequent signaling molecules, but they also amplify the initiating signals
to ultimately activate effector molecules and induce cell proliferation, differentiation and survival of
cervical cancer [51].
These pathways and functions were identified as overlapping biological themes, and these data
may provide useful information on the molecular mechanisms for cervical cancer, its prognosis and
treatment responses.
There are a number of novelties in this study: (1) this is the first report of CNAs in the relatively
ethnically homogeneous group of Mexican Americans using high density mapping (2.5 million in
number); previous studies using less density markers may result in an underestimation of the genetic
changes that take place in cervical cancer; (2) newly-identified CNAs in cases together with results in
the in silico analysis using KEGG and GO function provide insight into how multiple CNAs might
contribute to cervical cancer development. We also are aware of some limitations in our study. (1) Our
small sample size (14 cases and 125 references) is a major limitation for this type of study. Due to
a small number of samples, the nature of genome-wide alteration of copy number may not be fully
explained in pre-cancer and SCC. Future confirmation studies using an independent sample will
provide an opportunity to more accurately dissect the genetic complexity of somatic CNAs for cervical
cancer. (2) There might be a bias of the CNA identified in cervical cancer for the Mexican Americans,
since we used the 1000 Genome admixed populations, not Mexican Americans; thus, we currently
are recruiting more subjects with cervical cancer from the same population and plan to validate the
findings in more samples. (3) Other biomarkers, such as RNA-Seq or DNA methylation profile and
sequencing data using next generation sequencing technologies (such as target gene sequencing in
these CNA regions), will provide an opportunity for in-depth molecular profiling of the fundamental
biological processes of cervical cancer.
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We expect that with future validation and confirmation, newly-discovered CNAs can be used in
cancer classification, diagnosis, prognosis and treatment responses.
5. Conclusions
Using high density SNP array analysis, we have shown extensive genome-wide CNA changes
in pre-cancer and cancer groups as compared to the genome CNA profile in the reference group.
Our results demonstrated that the recurrent alterations of CNAs occurred in cases of pre-cancer
and SCC. Some of the somatic genomic gains and losses in cervical pre-cancer and cancer were in
concordance with the results from previous studies. To our knowledge, no previous studies have
applied genome-wide copy number analysis using such high density markers for cervical cancers
in the Mexican American population; however, validation and confirmation in a larger sample size
are needed.
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